- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04307277
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma (CHIC-STS01)
Phase III, multicenter, randomized open-label and comparative study designed to demonstrate whether adding 4 cycles of peri-operative doxorubicin-based chemotherapy improves metastasis-free survival as compared with standard management in patients with resectable STS, considered as high-risk according to CINSARC (Complexity Index in SARComas) signature.
After signed informed consent, patients considered as eligible to CHIC-STS study by the investigator will be enrolled in the study and a molecular screening will be performed (600 patients will be screened).
Patients considered as low-risk according to CINSARC signature will be treated at the discretion of the clinicians (prospective cohort).
Patients considered as high-risk according to CINSARC signature will be randomized in the open-label multicenter phase III trial and assigned in one of the two following treatments arms:
- Arm A (control arm): Standard of care (surgical excision +/- external radiotherapy).
- Arm B (experimental arm): Standard of care + 4 cycles of intravenous chemotherapy during 12 weeks.
A total of 250 patients will have to be randomized with 125 patients in each arm.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Thibaud VALENTIN
- Phone Number: 05 31 15 51 70
- Email: valentin.thibaud@iuct-oncopole.fr
Study Locations
-
-
-
Besançon, France
- Recruiting
- CHRU Besançon
-
Contact:
- Loïc CHAIGNEAU
- Phone Number: 03 81 47 99 99
- Email: lchaigneau@chu-besancon.fr
-
Bordeaux, France
- Not yet recruiting
- Institut Bergonié
-
Contact:
- Antoine ITALIANO
- Phone Number: 05 56 33 32 44
- Email: a.italiano@bordeaux.unicancer.fr
-
Caen, France
- Recruiting
- Centre François Baclesse
-
Contact:
- Zoé NEVIERE
- Phone Number: 02 31 45 50 11
- Email: z.neviere@baclesse.unicancer.fr
-
Clermont-Ferrand, France
- Recruiting
- Centre Jean Perrin
-
Contact:
- Pascale DUBRAY-LONGERAS
- Phone Number: 04 73 27 80 80
- Email: pascale.dubray-longeras@clermont.unicancer.fr
-
Dijon, France
- Recruiting
- Centre Georges-François Leclerc
-
Contact:
- Alice HERVIEU
- Phone Number: 03 80 73 75 06
- Email: ahervieu@cgfl.fr
-
Grenoble, France
- Not yet recruiting
- Chu Grenoble
-
Contact:
- Mathieu LARAMAS
- Phone Number: 04 76 76 38 42
- Email: mlaramas@chu-grenoble.fr
-
Limoges, France
- Recruiting
- CHU Limoges
-
Contact:
- Valérie LE BRUN-LY
- Phone Number: 05 55 05 63 96
- Email: valerie.lebrun@chu-limoges.fr
-
Lyon, France
- Recruiting
- Centre Léon Bérard
-
Contact:
- Armelle DUFRESNE
- Phone Number: 04 69 85 61 46
- Email: armelle.dufresne@lyon.unicancer.fr
-
Marseille, France, 13273
- Recruiting
- Institut Paoli-Calmettes
-
Contact:
- François BERTUCCI
- Phone Number: 04 91 22 35 37
- Email: bertuccif@ipc.unicancer.fr
-
Marseille, France
- Recruiting
- CHU Marseille
-
Contact:
- Florence DUFFAUD
- Phone Number: 04 91 38 54 39
- Email: florence.duffaud@ap-hm.fr
-
Montpellier, France
- Recruiting
- Institut de Cancérologie de Montpellier
-
Contact:
- Nelly FIRMIN
- Phone Number: 04 67 61 45 65
- Email: nelly.firmin@icm.unicancer.fr
-
Nice, France, 06189
- Recruiting
- Centre Antoine Lacassagne
-
Contact:
- Esma SAADA-BOUZID
- Phone Number: 04 92 03 15 14
- Email: esma.saada-bouzid@nice.unicancer.fr
-
Paris, France
- Recruiting
- Hôpital COCHIN
-
Contact:
- Pascaline BOUDOU-ROUQUETTE
- Phone Number: 01 58 41 17 46
- Email: pascaline.boudou@aphp.fr
-
Poitiers, France
- Recruiting
- CHU Poitiers
-
Contact:
- Nicolas ISAMBERT
- Phone Number: 05 49 44 45 38
- Email: nicolas.isambert@chu-poitiers.fr
-
Reims, France
- Recruiting
- Institut Godinot
-
Contact:
- Pauline SOIBINET-OUDOT
- Phone Number: 03 26 50 43 83
- Email: pauline.soibinet@reims.unicancer.fr
-
Rennes, France, 35042
- Recruiting
- Centre Eugene Marquis
-
Contact:
- Angélique BRUNOT
- Phone Number: 02 99 25 32 80
- Email: a.brunot@rennes.unicancer.fr
-
Rouen, France, 76038
- Recruiting
- Centre Henri Becquerel
-
Contact:
- Cécile GUILLEMET
- Phone Number: 02 32 08 22 37
- Email: cecile.guillemet@chb.unicancer.fr
-
Saint-Herblain, France
- Recruiting
- Institut de Cancérologie de l'Ouest
-
Contact:
- Emmanuelle BOMPAS
- Phone Number: 02 40 67 99 39
- Email: emmanuelle.bompas@ico.unicancer.fr
-
Saint-Étienne, France
- Withdrawn
- CHU de Saint Etienne
-
Strasbourg, France
- Recruiting
- Institut de cancerologie Strasbourg Europe
-
Contact:
- Justine GANTZER
- Phone Number: 03 88 11 51 41
- Email: j.gantzer@icans.eu
-
Toulouse, France
- Recruiting
- Institut Universitaire du Cancer Toulouse Oncopole
-
Contact:
- Thibaud VALENTIN
- Phone Number: 05 31 15 51 70
- Email: valentin.thibaud@iuct-oncopole.fr
-
Vandœuvre-lès-Nancy, France
- Recruiting
- Institut de Cancérologie de Lorraine - Centre Alexis Vautrin
-
Contact:
- Maria RIOS
- Phone Number: 03 83 59 84 61
- Email: m.rios@nancy.unicancer.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of soft-tissue sarcoma, histologically confirmed by RRePS (Réseau de Référence en Pathologie des Sarcomes et des Viscères) network.
- According to FNCLCC grading system, grade 1, 2 or 3 tumors.
- Resectable and localized disease after appropriate extension work-up (including at least a chest-CT).
- Available archived FFPE tumor sample in sufficient quantity to allow CINSARC qualification.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Life expectancy of at least 12 weeks after the start of the treatment.
- Women should be post-menopaused or willing to accept the use of an effective contraceptive regimen during the treatment period and at least 12 months after the end of the treatment period. All non-menopaused women should have a negative pregnancy test within 72 hours prior to registration.
- Signed written informed consent.
- Patient affiliated to a Social Health Insurance in France.
Exclusion Criteria:
- Soft-tissue sarcoma with the following histological subtypes: well-differentiated liposarcomas, alveolar soft-part sarcoma, dermatofibrosarcoma protuberans, clear-cell sarcoma, epithelioid sarcoma, alveolar or embryonal rhabdomyosarcoma.
- Primitive cutaneous, retroperitoneal, uterus or visceral STS.
- Metastatic disease.
- Previous or ongoing treatment for the sarcoma (with the exception of a surgery for diagnosis intend).
- Contra-indication for Doxorubicin, Ifosfamide and Dacarbazine treatments.
- Prior therapy with ifosfamide or cyclophosphamide or other nitrogen mustards, and prior therapy with anthracyclines.
- Prior mediastinal/cardiac radiotherapy.
- History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia, myocardial infarction within 6 months prior to study entry.
- Prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
- Known infection with HIV, hepatitis B, or hepatitis C.
- Women who are breastfeeding, pregnant or who plan to become pregnant while in the trial.
- Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
- Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
- Patient unable to comply with the protocol for any reason.
ADDITIONAL CRITERIA FOR THE RANDOMIZED PHASE III STUDY
- High-risk CINSARC signature.
- Acceptable hematologic function (within 72 hours of eligibility assessment): Absolute neutrophil count (ANC) ≥ 1.5 G/L, Platelet count ≥ 100 G/L and Hemoglobin > 9g/dL.
- Acceptable renal function within 72 hours of eligibility assessment: Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 60 mL/min (by the Cockcroft and Gault formula).
- Acceptable liver function: Bilirubin ≤ 1.5 x upper limit of normal (ULN), AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN.
- Normal LVEF (>50%) measured by echocardiography or isotopic ventriculography .
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental arm
|
Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)
|
Other: Control arm
|
Surgical excision with external radiotherapy (if applicable)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Metastasis-free survival defined by the delay between randomization and the appearance of metastatic.
Time Frame: 5 years for each patient
|
5 years for each patient
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival defined by the delay between randomization and death from any cause.
Time Frame: 5 years for each patient
|
5 years for each patient
|
Disease-free survival defined by the delay between randomization and first relapse (local, regional, or distant) or death from any cause.
Time Frame: 5 years for each patient
|
5 years for each patient
|
Safety assessed by the toxicity grading of the National Cancer Institute (NCI-CTCAE v5.0).
Time Frame: 4 months for each patient
|
4 months for each patient
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19SARC05
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Sarcoma
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
CytRxUnknownUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
National Institutes of Health Clinical Center (CC)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma | Stage IVB Adult Soft Tissue Sarcoma
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Centre Leon BerardNovartis; National Cancer Institute, FranceRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
UNICANCERRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
University of Colorado, DenverAgenus Inc.RecruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedSoft Tissue Sarcoma, Adult | Soft Tissue Sarcoma, ChildUnited States
Clinical Trials on Standard of care
-
Johns Hopkins UniversityRecruitingCompartment Syndrome of Leg | Extracorporeal Membrane Oxygenation Complication | Limb Ischemia, Critical | Limb IschemiaUnited States
-
brett rasmussenCompleted
-
Indonesia UniversityCompletedCovid19 | AcupunctureIndonesia
-
Aventusoft, LLC.National Heart, Lung, and Blood Institute (NHLBI); Cleveland Clinic FloridaRecruitingHeart Failure (HF)United States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedSevere COVID-19Israel
-
Ruijin HospitalRecruitingCOVID-19 PneumoniaChina
-
Institut Claudius RegaudCompletedMETASTATIC CANCERFrance
-
Ziv HospitalNot yet recruiting
-
Hofseth Biocare ASAKGK Science Inc.CompletedCovid-19 | COVIDCanada, Brazil, Hungary, Mexico, Serbia
-
City University of New York, School of Public HealthNew York State Psychiatric Institute; University of KwaZulu; International Initiative... and other collaboratorsCompleted